ClinicalTrials.gg
RecruitingNCT05502133Updated Sep 10, 2026

Identification of Acute Intermittent Porphyria Modifying Genes

An observational study in Acute Intermittent Porphyria (AIP), sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.

Started
2022
the only one that year
Observational
6 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Icahn School of Medicine at Mount Sinai

Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is the only one that started in 2022, is one of 6 observational ones, and was the 12th registered.

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Open to participants now

2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Porphyria, Acute Intermittent with a site in United States, or all of them as a file.
02

Study summary

This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.

03

Conditions studied

  • Acute Intermittent Porphyria (AIP)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above.

Eligibility criteria

Inclusion Criteria:

  • Willing and able to give
  • 12 years of age or older
  • Willingness to provide blood/saliva and urine samples, and clinical information
  • A member of an AIP family, defined as (must meet one of the following):

    1. proband: possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks in the opinion of the investigator)
    2. Parents (no known HMBS mutations or heterozygote with familial mutation)
    3. First, second, or third degree relative of (a) or (b)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Intermittent Porphyria (AIP)

    Symptomatic patients with Acute Intermittent Porphyria (AIP) A member of an AIP family who possesses an AIP pathogenic mutation and is/has been symptomatic (experienced acute attacks). Parents with no known HMBS mutations or heterozygote with familial mutation or a first, second or third degree relative of the above.

06

What researchers measure

Primary outcomes

  1. Odds ratios (OR) of the effects of identified modifier genes/variants

    There are no primary and secondary endpoints. This is an exploratory genetic study. Exploratory Endpoints: Odds ratios (OR) of the effects of identified modifier genes/variants. (If putative predisposing or protective gene variants are identified)

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Not feasible.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2029, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Aug 16, 2022
StartActual
Sep 23, 2022
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05502133
Responsible party
Robert Desnick (Dean for Genetics and Genomic Medicine Emeritus, Professor and Chair Emeritus, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Aug 16, 2022
Start date
Sep 23, 2022
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 10, 2026

Study contacts

Chloe Cheung
Contact
chloeyihang.cheung@mssm.edu
646-369-2045
Robert J Desnick, Ph.D, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion